In studies to determine the optimal treatment for polycythemia vera, 431 previously untreated
patients whose disease met established diagnostic criteria were entered into a prospective, …

Nonradiomimetic drugs, hydroxyurea (HU) and pipobroman (Pi), were administred to relatively
young subjects with polycythemia vera (PV) in an attempt to decrease the leukemogenic …

Despite myelosuppression, polycythemic (PV) patients greater than 65 years of age have a
high risk of vascular complications, and the leukemic risk exceeds 15% after 12 years. Is the …

Conventional treatment of polycythemia vera (PV) with radioactive phosphorus or alkylating
agents is associated with a significant excess of acute leukemia and cancer of the …

In the presence of aplastic anemia (AA), therapeutic choices should be determined while
taking into account not only changes for immediate improvement, but also both the risks for late-…

The very‐long‐term follow‐up of patients initially included in the PVSG protocols provides
useful information. The excess risk of cancer after chlorambucil appears to persist for 5 years …

Acute promyelocytic leukemia (APL) is a homogeneous subgroup of acute myeloid leukemias
(AMLs) characterized by the presence of the t(15,17) translocation and the resulting …

On the basis of a retrospective study of 3600 platelet kinetic studies, we have isolated 54
cases with chronic thrombocytopenia, a normal autologous and homologous platelet lifespan, …

An analysis of the risk of progression towards leukemia, carcinoma and myelofibrosis was
performed in 93 patients treated by 32 P alone (PVSG protocols) since 1970-1979, 395 …

Over 20 years, 58 cases of PV in young people (46 meeting the full PVSG criteria, 12 with
elevated red cell volume and leucocytosis or thrombocytosis, without splenomegaly) were …